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Panel 1. Search strategy and selection criteria: 
References for this Review were identified through searches of Medline with the search term 
“germ cell tumour” from 1990 until 2015. We included older, seminal publications that underpin 
understanding of the topic. Only papers published in English were reviewed. The final reference 
list was generated on the basis of relevance, historical impact, and opportunities for further 
reading.  
 
Panel 2. Chemotherapy regimen abbreviations: 
BEP: bleomycin (weekly dosing), etoposide, cisplatin 
Accelerated BEP: BEP with the cisplatin/etoposide component administered every 2 weeks 
CA/PVB: cyclophosphamide, actinomycin-D, cisplatin, vinblastine, bleomycin  
CEB or BEC: carboplatin, etoposide, bleomycin (weekly dosing) 
CEb: carboplatin, etoposide, bleomycin (paediatric trials, once per cycle bleomycin) 
C-PEb: cyclophosphamide, cisplatin, etoposide, bleomycin 
CBOP-BEP: carboplatin, bleomycin, vincristine, cisplatin + BEP 
EP: etoposide, cisplatin 
GETUG-13: BEP x1, paclitaxel/oxaliplatin/BEP x2, cisplatin/ifosfamide/bleomycin x2  
HD-PE: high-dose cisplatin (150 mg/m
2
/cycle), etoposide 
HD-PEb: high-dose cisplatin (200 mg/m
2
/cycle), etoposide, bleomycin  
JEb: carboplatin, etoposide, bleomycin (paediatric trials; once per cycle bleomycin) 
PEb: cisplatin, etoposide, bleomycin (paediatric trials; once per cycle bleomycin) 
PEI: cisplatin, etoposide, ifosfamide 
PVB: cisplatin, vinblastine, bleomycin 
TI-CE: paclitaxel and ifosfamide followed by high-dose carboplatin and etoposide 
TIP: paclitaxel, ifosfamide, cisplatin 
VIP (or VeIP): vinblastine, ifosfamide, cisplatin 
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SUMMARY 
The management of paediatric extracranial germ cell tumours (GCTs) carries a unique set of 
challenges. GCTs are a heterogeneous group of neoplasms that present across a wide range of 
age, site, histology, and clinical behaviour. They are managed by a diverse variety of specialists. 
Correspondingly, their staging, risk-stratification, and treatment approaches have evolved 
disparately along multiple trajectories. Paediatric GCTs differ from the adolescent and adult 
disease in many ways, leading to complexities in applying age-appropriate evidence-based care. 
Suboptimal outcomes remain for several patient groups,and among survivors there are significant 
long-term toxicities. The challenge moving forward will be to translate new insights from 
molecular studies and collaborative clinical data into better patient outcomes. Future trials will 
be characterized by improved risk-stratification systems, biomarkers for response and toxicity, 
rational reduction of therapy for low-risk patients and novel approaches for high-risk patients, 
and improved international collaboration across paediatric and adult cooperative research groups.      
 
 
 
 
  
INTRODUCTION 
 
Although often referred to as a rare paediatric cancer, malignant GCTs (MGCTs) represent 3.5% 
of all childhood cancers that occur before 15 years (y) of age, making them approximately as 
common as childhood rhabdomyosarcomas, osteosarcomas, or retinoblastomas.
1
 In adolescents 
aged 15-19y, however, MGCTs represent 13.9% of neoplasms, becoming the most common 
solid tumour and the second most common malignancy, after Hodgkin lymphoma, in this age-
group. Based on data from the Surveillance, Epidemiology and End Results (SEER) database, 
the United States (US) age-adjusted incidence of extracranial GCTs is 11.7 per million in boys 
and 6.7 per million in girls. There are about 900 new cases of MGCT diagnosed in the US each 
year in patients <20y. There are two distinct peaks in incidence, one in young children (0-4y) and 
another from the onset of puberty through young adulthood.
2
  
 
 
BIOLOGY 
 
A better understanding of the molecular basis of GCTs may allow improved risk-stratification 
and identification of targets for the development of novel therapies, with the aim of improving 
overall survival for high-risk groups and rationalising therapy reductions in low-risk groups.  
 
 
Aetiology. GCTs are hypothesised to occur as a result of events in utero, although the aetiology 
remains largely unknown. Strong heritability estimates suggest a genetic susceptibility.[ref4] 
Potential risk factors include parental demographic characteristics, in utero chemical or hormone 
exposures, parental lifestyle factors, and congenital abnormalities.
3
 Of these, cryptorchidism and 
Klinefelter syndrome are associated with an increased risk of testicular and mediastinal tumours 
in boys. Disorders of sexual differentiation such as Frasier syndrome,, Swyer syndrome, and 
other androgen insensitivity syndrome are associated with an increased risk of GCTs in the 
streak gonads, principally gonadoblastoma.  
 
Development. GCTs arise from early germline progenitors known as primordial germ cells 
(PGCs). The totipotent nature of PGCs explains the wide variety of possible GCT histologies 
observed (Figure 1). A widely held hypothetical model of tumorigenesis proposed by Teilum
5
 
(Figure 2) views germinomas (seminomas and dysgerminomas in testicular and ovarian sites, 
respectively) as arising directly from undifferentiated PGCs and therefore retaining pluripotency. 
Embryonal carcinomas (EC) display early embryonic differentiation. These may further 
differentiate into tumours containing all three germ layers (endoderm, ectoderm and mesoderm), 
termed teratomas. In contrast, those that follow an extra-embryonic differentiation pathway 
result in either yolk sac tumours (YST; formerly endodermal sinus tumours), or 
choriocarcinomas (CC; tumours resembling the trophoblast).
6
 Tumours that contain multiple 
malignant histologies are termed mixed MGCTs.      
 
PGCs migrate from the yolk sac to the gonadal ridge during early gestation through the midline 
of the developing embryo. Several factors are required for the survival and migration of PGCs, 
including the chemokine receptor CXCR4, and the KIT ligand KITLG,
4, 7
 which is expressed in 
an increasing gradient to the gonadal ridge. Disruption of this migration process may explain the 
occurrence of extragonadal GCTs and their midline propensity. Recent genome wide association 
studies (GWAS) have implicated single nucleotide polymorphisms (SNPs) in the KITLG gene in 
the development of GCTs in adults and adolescents. More than 25 SNPs in genes at 19 
independent loci have been identified. These genes are implicated through five main 
mechanisms, including KIT/KITLG signalling, male germ cell development, telomerase, 
microtubule and DNA damage repair pathways. Observed odds ratios are the highest reported for 
any cancer type. In the future, it may be possible to derive a polygenic risk-score to inform 
potential screening strategies. It remains to be determines exactly how many of these SNPs are 
relevant to paediatric tumours.    
 
Epigenetics. Epigenetic mechanisms may also contribute to GCT development.
8
 Migrating PGCs 
undergo erasure of methylation at so-called imprinted genes, followed by gender-specific re-
imprinting during gametogenesis.
9
 The imprinting patterns of loci such as IGF2/H19 differ in 
paediatric GCTs, suggesting that tumours arise from earlier stages of PGC development in 
children. In paediatric MGCTs, YSTs have increased methylation at many gene regulatory loci 
compared with germinomas, including silencing of genes associated with apoptosis and 
suppression of WNT signaling.
10
 
 
Genomics. Gain of chromosome 12p is a universal feature of adult testicular MGCTs, regardless 
of histological subtype, usually due to isochromosome 12p formation.
11
 Seminomas and EC 
express key stem cell genes in this 12p region including NANOG and STELLA/DPPA3, which 
may block differentiation and favour cell proliferation. 12p gain is present but less common in 
MGCTs of young children, and the frequency increases over childhood with increasing age.
12
 
Additionally, gains of chromosomes 1q, 11q, 20q, 22q, and loss of 1p, 6q and 16q have been 
described in paediatric GCTs.
13
 However, the clinical relevance of 12p gain and other genomic 
abnormalities in MGCTs has not yet been established. High-resolution genomic studies will 
likely identify copy number variations (CNVs) that are associated with clinical outcome and may 
be incorporated into future risk-stratifications.   
 
Gene expression. The two most common histological subtypes of MGCTs, YST and germinoma, 
exhibit distinct messenger RNA (mRNA) gene expression patterns. As in adult disease, 
paediatric germinomas express pluripotency genes [NANOG, POU5F1 (OCT3/4), TFAP2C, and 
UTF], whereas paediatric YSTs express genes relevant to differentiation (KRT8, KRT19), lipid 
metabolism (APOA1, APOA2), and proliferation pathways.
14
 However, these profiles segregate 
paediatric GCTs from adult testicular GCTs of the same histological subtype (Figure 3A), 
suggesting that different gene expression programmes may be driven at least in part by the 
alterations in hormonal status that accompany puberty. At present, the differential age-related 
mRNA profiles in the GCTs described have not been shown to be prognostic. However, a 
prognostic mRNA gene expression signature predictive of overall survival has been identified 
and validated in adult males with MGCTs and further validation is underway.
15
 A central goal of 
upcoming studies is to determine whether suchsignatures are prognostic in children..   
 
Non-protein-coding RNAs represent another promising area of investigation in GCTs. The 
pluripotency gene LIN28 is expressed in all malignant GCTs across age-groups and histologies.
16
 
The best understood function of LIN28 is to prevent biogenesis of the let-7 tumour suppressor 
family of microRNAs (miRNAs). MiRNAs are short 18-23 nucleotide RNAs that regulate the 
expression of target mRNAs. Indeed, mRNA targets of let-7 are upregulated in MGCT cells, 
including known oncogenes such as MYCN, making the LIN28/let-7 pathway a promising target 
for therapeutic intervention.  The oncogenic miR-371~373 and miR-302/367 clusters
17
 (see 
Figure 3B) are over-expressed in all MGCTs, regardless of age, site, or histologic subtype. 
Importantly, elevated levels of these miRNAs can be detected in the serum at the time of MGCT 
diagnosis
 
as well as at relapse, and decline in response to treatment.
18
 Measuring circulating 
miRNA levels provides greater sensitivity and specificity for detecting MGCTs than the 
conventional protein biomarkers alpha-fetoprotein (AFP) and/or human chorionic gonadotrophin 
(HCG) and thus may represent a universal blood-based biomarker.
19, 20
  
 
Biochemical signaling pathways. As embryonal tumours, GCTs are frequently enriched for the 
expression of genes associated with normal embryonic development. A recent integrated analysis 
of methylation, miRNA, and protein-coding gene data confirmed differences by GCT histology 
[Poynter BMC]. In addition, YSTs exhibit gene expression and biochemical evidence of WNT 
pathway signaling, in contrast to germinomas where this rarely occurs.
21
 Similarly, differential 
protein-coding gene expression leads to activation of the TGF-beta/BMP pathway in YSTs, 
whereas BMP pathway activity is absent in germinomas.
22
 However, WNT and BMP pathways 
currently offer few possibilities for targeted therapies. In contrast, the prominent role of the KIT 
tyrosine kinase in germ cell biology suggests that this kinase or its downstream targets, the 
PI3K/AKT/mTOR and RAS/RAF pathways, may offer a more immediate target.
23
 For example, 
KIT gain-of-function mutations (D816V, D816H) activate the PI3K pathway in seminomas, even 
in the absence of KITLG. Unfortunately, responses to the KIT tyrosine kinase inhibitor imatinib 
in clinical studies have been disappointing, with no complete or even partial remissions reported.  
 Other recent research advances have focused on identifying mechanisms of cisplatin resistance. 
A limited study, interrogating only seven genes, found somatic mutations in PIK3CA, AKT, 
KRAS and NRAS may contribute to cisplatin resistance in adult testicular GCTs. A recent whole 
exome sequencing (WES) study in adult testicular GCTs revealed a low mutation rate (43%) 
compared with other human cancers.
24
 Two treatment-refractory patients were shown to harbour 
XRCC2 mutations, which may therefore be implicated in cisplatin resistance.
24
 Recent WES 
studies in intracranial GCTs have also identified known (KIT, RAS) and novel (JMJD1C) 
mutations that may improve our understanding of extracranial GCT development, given their 
presumed common origin. Further research in MGCTs is required to fully understand the clinical 
impact of these biological insights, to incorporate molecular findings into risk-stratifications, and 
to prioritise new therapeutic approaches. For example, further study of the molecular 
epidemiology of paediatric GCTs is planned in a large case-parent triad study within the 
Children’s Oncology Group (COG) (NCI-R01-CA151284). 
 
 
CLINICAL PRESENTATION 
 
The diagnosis of a GCT should be considered for any midline tumour. The most common sites of 
extracranial presentation include the gonads (testes/ovaries), sacrococcyx, retroperitoneum, and 
mediastinum. Metastatic disease occurs in 20% of cases at diagnosis and most commonly 
involves the lungs, but can involve bone, bone marrow, liver, or brain.
25
 
 
Sacrococcygeal GCTs can present around birth as a large exophytic mass.
26
 The differential 
diagnosis in this age-group is limited, although large haemangiomas or neuroblastic tumours 
may occasionally lead to diagnostic uncertainty. These sacrococcygeal GCTs are frequently 
detected antenatally on routine imaging and, if very large, can result in hydrops fetalis or 
obstruction of labour. These tumours are three times more common in girls than boys, and are 
usually teratomas with or without components of YST. Sacrococcygeal GCTs can also present 
after the neonatal period, usually <3y. In the absence of an external palpable mass, they are more 
likely to present as pain on sitting, buttock asymmetry, or bladder, bowel, or lower limb 
dysfunction. These later-diagnosed tumours are more likely to have undergone malignant 
transformation to include YST components.
27
 
 
Testicular GCTs usually present as a painless swelling of one testis. They occur either before 4y 
(predominantly as pure YSTs or teratomas) or after puberty (predominantly as mixed MGCTs or 
seminomas).
2
 The differential diagnosis includes hydrocoele, infection, torsion, sex cord stromal 
tumour, leukaemia, or paratesticular rhabdomyosarcoma. 
 
Ovarian GCTs typically present with the gradual onset of abdominal distension and discomfort 
and a pelvic mass.
28
 Severe acute pain often indicates torsion, rupture or haemorrhage within the 
tumour. The peak incidence begins with the onset of thelarche around age 8y. Their histology 
can include mature (MT) or immature (IT) teratoma, dysgerminoma, YST, or mixed MGCT. A 
particular feature of ovarian IT is the propensity for peritoneal seeding as nodules of mature glial 
tissue, known as peritoneal gliomatosis. The differential diagnosis of an ovarian tumour in 
children can include benign ovarian cysts, sex cord stromal tumours, or rarely an adult-type 
ovarian epithelial carcinoma.  
 
Mediastinal GCTs present with symptoms caused by airway compression, superior vena cava 
obstruction, or heart failure.
29
 In prepubertal children, these tumours are usually teratomas. In 
adolescents, most commonly males, mediastinal GCTs typically contain a mixture of malignant 
components (YST, EC, CC) and teratoma, as well as possible non-germ cell components such as 
primitive neuroectodermal tumour.
30
 The main differential diagnosis is lymphoma, which is 
usually the first consideration, until the results of tumour markers become available. 
 
 
DIAGNOSTIC INVESTIGATIONS 
 
Elevated serum levels of the conventional protein tumour markers AFP and HCG assist in the 
diagnosis of YSTs and CC, respectively.
31
 Some elevation of AFP can be seen in EC or in 
teratomas that recapitulate endodermal elements or liver tissue, and some elevation of HCG can 
be seen in germinomas that contain syncytiotrophoblast (Figure 2). Consequently, AFP and HCG 
are not completely sensitive, as tumours without these histologies do not secrete tumour markers. 
It is estimated that 70% of non-germinomatous GCTs and 20% of germinomas are secreting.  
 
Conversely, elevated tumour markers are also not specific for GCTs. The differential diagnosis 
of elevated AFP includes hepatoblastoma, hepatocellular carcinoma, liver surgery or 
inflammation, hemangioendothelioma of the liver, pancreatoblastoma, ataxia telangiectasia, and 
hereditary persistence of AFP.
32
 Additionally, physiological elevation of AFP is seen during 
infancy. Therefore, an elevated AFP in an infant must be interpreted in the context of age-
adjusted values and serial measurements. Two studies
33, 34
 have catalogued the normal range of 
AFP in infants, and their results (Supplemental Table 1) provide a useful reference for clinicians. 
The differential diagnosis of an elevated HCG includes pregnancy, gestational trophoblastic 
disease, and rarely other hepatic or neuroendocrine tumours.
31
  
 
The level of tumour markers at diagnosis has been shown to be predictive of prognosis in adult 
testicular GCTs and forms part of the IGCCCG criteria.
35
 However, studies of paediatric GCTs 
have not consistently observed the same association.
36
 The rate of decline of AFP has also been 
shown to be prognostic in adult GCTs,
37
 but has not been formally evaluated in paediatric 
disease.  
 
Other diagnostic investigations should include imaging of the primary tumour (ultrasound for 
testicular disease, cross-sectional imaging with MRI or CT scan for other sites) and potential 
metastatic sites (CT chest scan, bone scan, MRI head in stage IV CC).  
 
Definitive diagnosis is based on histology. Most gonadal  tumours are surgically resected upfront 
and therefore do not usually require pre-operative biopsy. Unresectable tumours requiring 
neoadjuvant chemotherapy should be biopsied in most cases. When it is unsafe to biopsy, the 
combination of typical radiological appearance and elevated conventional tumour markers may 
be sufficient to make a diagnosis and start neoadjuvant chemotherapy.       
 
 STAGING AND RISK GROUPS 
 
Adult and paediatric cooperative groups have historically used different systems for staging and 
risk-stratification.  
 
Clinicians treating adult patients with testicular tumours use the AJCC/TNM system for staging
38
 
and the IGCCCG
35
 for risk-stratification in metastatic disease (Supplemental Tables 2 and 3). 
Those treating adult patients with ovarian tumours utilise the FIGO system (Supplemental Table 
4).
39
 Paediatric groups utilise various post-surgical staging systems, but generally use stage I to 
refer to completely resected tumours, stage II for microscopic residual disease or persistently 
elevated tumour markers after resection, stage III for gross disease or nodal involvement, and 
stage IV for distant metastases (Supplemental Table 5 and 6).
40, 41
 There are confusing 
inconsistencies resulting from the multiple staging systems. For example, an ovarian tumor with 
positive peritoneal cytology would be stage IC by FIGO but stage III by COG staging. A 
metastatic testicular tumor would be stage III by AJCC but stage IV by COG staging. These 
differences have made conversations and collaborations between different treating groups 
challenging.    
 
The combination of site and stage assigns patients to risk-groups. While risk strata have also 
varied across cooperative groups and over time, nearly all risk-stratification systems are based 
upon the concept of a trichotomous ‘functional’ classification.In this scheme, a low-risk group is 
defined as one where patients can be managed with resection alone, followed by active 
surveillance. The research priority for this group is determining whether patients other than those 
with testicular stage I disease can be safely managed with this approach. An intermediate-risk 
group includes those patients who do require chemotherapy but who have excellent outcomes 
with current regimens. The research priority for these patients is maintaining the high cure-rates 
while reducing late-effects. Lastly, a high-risk group represents patients who have unsatisfactory 
outcomes with current regimens and for whom further improvements in cure-rates are still 
needed.  
 
Recently, investigators from COG and the Children’s Cancer and Leukaemia Group (CCLG) 
assembled a large pooled database of over 1100 children with extracranial MGCTs treated across 
seven clinical trials, termed the Malignant Germ Cell Tumours International Collaborative 
(MaGIC). The database was used to develop an updated paediatric MGCT risk-stratification 
system (Table 2).
36
 Age ≥11y and tumour site and stage were significant predictors of worse 
long-term disease-free survival. For example, those ≥11y and either stage III/IV extragonadal or 
stage IV ovarian tumours had predicted survival of <70%. These results will form the basis of 
new paediatric risk-groups for future trials.  
 
 
SURGERY 
 
While MGCTs have historically been treated with upfront resection and adjuvant chemotherapy, 
there is no clear difference in cure-rates between upfront or post-chemotherapy resection.
27
 
Aggressive resections at initial presentation are not necessary if neoadjuvant chemotherapy can 
help reduce surgical morbidity.  
 
Testicular. An inguinal approach with early vascular control of the spermatic cord is indicated in 
all cases of testicular tumours.
42
 A trans-scrotal approach should never be used as this disrupts 
lymphatic channels and upstages the patient. Pre-pubertal boys with a normal AFP can have 
testis-sparing surgery with enucleation of the intact tumour if possible, because the diagnosis is 
likely to be either a teratoma or testicular stromal tumour. Pre-pubertal boys with an elevated 
AFP should have radical orchiectomy without violation of the tumour capsule in the surgical 
field. There is no role for retroperitoneal lymph node dissection (RPLND) in pre-pubertal boys.  
 
After puberty, all testicular GCTs, including teratomas, are associated with precursor lesions 
within the adjacent testicular tissue known as intratubular germ cell neoplasia (ITGCN). Hence, 
radical inguinal orchiectomy is required. The role of RPLND in adolescents with enlarged lymph 
nodes is unclear, and treating clinicians should follow adult guidelines here.
43
 Commonly, 
chemotherapy is utilised after orchiectomy, and RPLND is used selectively for those with 
residual nodal enlargement or elevated AFP/HCG at the end of chemotherapy. 
 
Ovarian. The majority of ovarian masses in children are benign cysts. However, if tumours are 
large, solid, or associated with elevated AFP/HCG, they should be approached as a suspected 
GCT. The involved ovary and tumour should be resected intact, with no morcellation and no 
deliberate interruption of the capsule, as these will affect histopathological staging.
44
  Given the 
importance of stage in determining adjuvant chemotherapy use, complete surgical staging is 
mandatory. The recommended components of surgical staging are collection of peritoneal fluid 
or washings for cytology, inspection and palpation of peritoneal surfaces, omentum, 
retroperitoneal lymph nodes, and the opposite ovary, with biopsies of any areas of abnormality.
45
 
Peritoneal fluid or washings can have positive cytology even when inspection of all tissues is 
normal. If the contralateral ovary was not clearly seen on pre-operative imaging, a pre-operative 
karyotype and intra-operative search for a streak gonad should be pursued. In bilateral ovarian 
involvement, neoadjuvant chemotherapy and delayed resection may allow the possibility of 
fertility-sparing surgery.  
 
Extragonadal. Most neonatal sacrococcygeal tumours are benign teratomas, and complete 
surgical resection including the coccyx is necessary to reduce the recurrence risk.
27
 Continued 
follow-up with serial AFP levels, rectal exams and/or ultrasound imaging is required, due to a 
YST recurrence rate of up to 14%.
46
 For sacrococcygeal tumours diagnosed beyond the neonatal 
period, data from the German MAKEI trials demonstrated improved outcome with neoadjuvant 
chemotherapy followed by delayed tumour resection.
27
  
 
The surgical approach to a mediastinal primary tumour may be through a thoracotomy or 
sternotomy. Retroperitoneal primary tumours require generous trans-abdominal exposure. 
Complete resection of these tumours is challenging but is generally required for cure, despite 
associated morbidities.
47
  
 
 
CHEMOTHERAPY 
 ADULT TRIALS 
Due to the epidemiology of GCTs, much of our understanding of the role of chemotherapy is 
based on investigations in the population of adult men with testicular cancer.  
Prior to the 1970s, testicular cancers were treated with sarcoma regimens, with poor responses. 
The major breakthrough came in 1977, when Einhorn and Donahue used the cisplatin, 
vinblastine, and bleomycin (PVB) regimen, obtaining 100% response and 64% survival in men 
with disseminated testicular GCTs.
48
 This discovery was recently named as one of the top five 
advances in 50 years of modern oncology by the American Society of Clinical Oncology 
(ASCO).
49
 Etoposide was introduced in the 1980s, and a subsequent randomised trial showed the 
superiority of bleomycin, etoposide, and cisplatin (BEP) over PVB.
50
   
 
In the 1990s, the IGCCCG developed a risk-stratification system for metastatic GCTs 
(Supplemental Table 3), categorising them as good-, intermediate- or poor-risk based on the 
combination of disease sites and AFP, HCG and lactate dehydrogenase (LDH) levels.
35
 In the 
good-risk group, clinical trials attempted to reduce the late-effects of BEP while maintaining 
excellent cure-rates through various strategies. Five randomised controlled trials (RCTs) 
investigated substituting carboplatin for cisplatin,
51, 52
 and another five RCTs investigated 
reducing or eliminating bleomycin,
53
 but BEP produced superior outcomes and remained the 
standard regimen.
54
 Two RCTs found that, in men with good-prognosis GCTs, three cycles of 
BEP were non-inferior to four.
55, 56
 In the intermediate- and high-risk groups, multiple 
intensification strategies were tested against four cycles of BEP, but none have shown improved 
survival. The GETUG-13 trial recently showed a small improvement in EFS after intensification 
for men with poor tumour marker decline, but utilising a complex regimen whose 
generalisability and adoption remain to be established.
57
  
 
 
PAEDIATRIC TRIALS 
 
While building on the results of studies in adult MGCTs, paediatric oncology collaborative 
groups have modified and tested these approaches. The results of paediatric trials for MGCTs are 
summarised in Table 2.   
 
In the 1990s, the North American Pediatric Oncology Group (POG) and the Children’s Cancer 
Group (CCG) conducted two intergroup studies to determine the optimal management of 
children with MGCTs.
58, 59
 These studies incorporated the cisplatin, etoposide and bleomycin 
combination as developed in adult studies. However, due to the fear of excessive pulmonary 
toxicity in the developing lungs of children, the frequency of bleomycin was reduced from once 
every week to once every three weeks per cycle. Of note, the reduced frequency of bleomycin 
was not studied in a comparative manner against the weekly administration. This modified 
regimen is often referred to as PEb, to distinguish it from the adult regimen BEP. In contrast, the 
German MAKEI 96 study eliminated bleomycin entirely and substituted ifosfamide for advanced 
tumors.   
 
The POG9048/CCG8882 study (INT-0106)
59, 60
 successfully treated  pre-pubertal boys with 
stage I testicular MGCTswith surgical resection and surveillance alone, as had been done for 
adult patients.
61
 
60
 Secondly, it showed excellent outcomes in children with intermediate-risk 
MGCTs treated with PEb.
59
 The second intergroup study, POG9049/CCG9981 (INT-0097) 
investigated whether a two-fold cisplatin dose escalation  could improve survival in high-risk 
patients.
40
 While EFS improved, the utility of the high-dose strategy was limited by its 
significant ototoxicity. In the high-dose arm, 67% of children required hearing aids, compared to 
10% in the standard-dose arm.   
 
The intergroup studies were followed by the next generation of studies by COG, AGCT0132 and 
AGCT01P1. For low-risk patients, AGCT0132 attempted to extend the strategy of surgery and 
active surveillance
42
 to stage I ovarian tumours, with PEb chemotherapy reserved for 
recurrences.
45
 The 4-year EFS was 52% and OS was 96%. Thus, half of all patients could be 
spared the morbidity of chemotherapy, and almost all patients with recurrence could be rescued. 
The single patient who died in this study had chemo-refractory disease from the outset of 
therapy. 
 
For intermediate-risk patients, AGCT0132 investigated whether a reduction in therapy to three 
cycles of PEb could achieve equivalent outcomes to a matched historical cohort that received 
four cycles. In the overall analysis, EFS was significantly lower with three cycles. Post-hoc 
analyses showed that three cycles could be associated with excellent outcomes in lower-stage 
patients, but the study was not specifically powered for subgroup analyses.  (Shaikh et al., 
unpublished). Therefore, four cycles of PEB remain the current standard. For high-risk patients, 
AGCT01P1 investigated combining cyclophosphamide with PEb.
62
 but no clear improvement in 
EFS was evident..  
 In the United Kingdom (UK), a series of single-arm trials (GCI to GCIII) conducted by the 
CCLG substituted carboplatin for cisplatin with the goal of reducing the rate of long-term 
toxicities while maintaining high cure-rates.
41, 63
 While adult trials had shown carboplatin to be 
inferior to cisplatin, the adult trials had generally used carboplatin at a lower dose, intensity, or 
frequency than the CCLG.
52
 The GCII trial used carboplatin 600mg/m2 every three weeks, 
corresponding to a median area-under-the-curve (AUC) of 7.9 mg/ml/min. For 137 children 
treated with JEB in this trial, the 5-year EFS was 88% and OS was 91%, which was comparable 
to the outcomes using PEb, but with no reports of sensorineural hearing loss.
41
 These results 
suggested that carboplatin could be a potential alternative to cisplatin in children when used in 
sufficient doses. This hypothesis forms the basis of an upcoming collaborative trial.  
 
Several important clinical trials of paediatric GCTs have been conducted by cooperative groups 
in Germany,
64, 65
 France,
66
 Brazil,
67
 and other centres. Their characteristics and results are 
summarised in Table 1, and readers are referred to the relevant references for further reading.    
 
 
SPECIAL SCENARIOS 
 
Teratomas. Teratomas are classified as MT (containing only well-differentiated tissues) or IT 
(containing less differentiated tissues including neuroectoderm). IT is graded from 0 to 3 based 
on the amount of immature neuroectodermal elements seen per microscopy field. MTs are 
managed by surgical resection alone. The management of ITs, particularly the need for adjuvant 
chemotherapy, has been controversial. Based on a historic study, which observed a 70% relapse 
rate in adult women with grade 3 ovarian IT, adjuvant chemotherapy has commonly been used 
by gynaecological oncologists
68
. However, paediatric trials did not confirm this observation. In a 
study by the CCLG,
46
 the EFS of 124 IT patients treated with surgery alone, regardless of grade 
or stage, was 86%. In a parallel COG trial,
69
 the EFS of 73 patients also observed after surgery 
without adjuvant chemotherapy was 93%.. In a recent pooled analysis, the risk of recurrence was 
seen primarily in patients with grade 3 stage III tumours. At present, most paediatric oncology 
groups do not utilise chemotherapy for IT. Teratomas with an MGCT component should receive 
chemotherapy directed to the malignancy. The MaGIC group is working on next steps for a joint 
paediatric-adult clinical trial for IT.  
 
 
 
Adolescent and young adults (AYA). As paediatric oncologists have historically managed most 
patients <18y in North America or <16y in the UK, some adolescents have been treated with 
approaches developed for young children. Therefore, they may not be risk-stratified using the 
IGCCCG criteria, receive the added intensity of weekly bleomycin, or have the opportunity to 
receive a lower cumulative dose of cisplatin in the IGCCCG good-risk group. However, 
adolescent MGCTs more closely resemble the epidemiological and clinical characteristics of 
adults. Recently, the outcome for adolescents was shown to be worse than for young children 
and adults with testicular tumours.
70
 We have also validated this observation within the MaGIC 
database (Frazier et al., unpublished). Compounding the poorer AYA outcomes is the 
observation that adolescents with MGCTs are under-represented in clinical trials, frequently 
missing the age inclusion criteria of both paediatric and adult studies. This represents a potent 
example of the ‘AYA gap’ in cancer care and research.71    
 
It is generally accepted that age-appropriate therapy is best delivered in an age-appropriate 
environment. The approach to AYA cancer care has started to change with the recognition of the 
specific medical and psychological needs of AYA patients, e.g. national UK referral pathways 
have been developed to ensure access to cancer care in specialist AYA treatment centres.
72
  
 
 
FUTURE TRIALS AND COLLABORATIONS 
 
There are several planned and upcoming clinical trials for paediatric GCTs. A hallmark of each 
of these trials is international and transdisciplinary collaboration.   
 
The AGCT1531 trial will be a collaborative effort involving the COGand national paediatric 
oncology centres in UK, Brazil, India, and Japan.. As well, it will be co-sponsored by the 
National Research Group (NRG) Oncology and will enroll adult patients through the National 
Clinical Trials Network (NCTN) mechanism in the US.    
 
The trial will include a low-risk and a standard-risk arm. For the low-risk group of patients, the 
trial will evaluate whether a strategy of complete surgical resection followed by surveillance can 
maintain an OS rate of ≥95% for paediatric, adolescent and adult patients with stage I MGCT at 
any site (testicular, ovarian, or extragonadal). The low-risk group will thus be expanded to 
include stage I extragonadal disease and will include patients up to age 50. 
 
For the standard-risk group, the trial will compare the EFS of a carboplatin- versus a cisplatin-
based regimen for paediatric, adolescent and young adult patients with MGCTs of all primary 
sites. Patients <11y will be randomised to CEb or PEb, while patients 11-25y will be randomised 
to BEC or BEP.    
 
For the high-risk group, current plans are for paediatric groups to join ongoing exploratory trials 
of promising regimens, such as the Australian and New Zealand Urogenital and Prostrate 
(ANZUP) group trial of compressed BEP, where the cisplatin and etoposide components are 
administered every two weeks instead of three. Thereafter, the combined adult gynaecological 
oncology, adult testicular and paediatric groups plan to launch an international multi-arm 
randomised trial comparing among the most promising regimens for high-risk MGCTs.   
 
For relapsed patients, the Alliance-sponsored study AO31102, referred to as the TIGER trial, 
will compare survival of male patients randomised to conventional chemotherapy with 
paclitaxel, ifosfamide and cisplatin (TIP) versus a regimen consisting of two cycles of paclitaxel 
and ifosfamide followed by three cycles of high-dose carboplatin and etoposide with stem-cell 
rescue (TI-CE).
73
 It will also prospectively evaluate the properties of the International Prognostic 
Factor Scoring Group (IPFSG) system
74
 as a predictor of outcome after relapse. The trial will be 
made available to adolescent patients >14y through a co-sponsorship with the COG.  
 
Biological aims of these upcoming trials include defining robust biomarkers and molecular 
signatures that predict risk of disease progression or chemoresistance, evaluating the potential for 
serum miRNAs as sensitive and specific tumour markers for malignant disease response and 
recurrence, investigating the pharmacogenomics of chemotherapy and late-effects, and 
identifying targets for novel therapeutic agents. It is likely that further progress for the high-risk 
group of patients will be achieved primarily through novel approaches, including the 
identification of molecular targets.       
 
 
LATE-EFFECTS 
 
Because most children with GCTs are cured, treating clinicians need to be aware of, and try to 
mitigate, late-effects of treatment. However, GCTs were not included in the Childhood Cancer 
Survivor Study, and hence knowledge of late-effects is largely extrapolated from the experience 
of adult patients treated for testicular cancer.  
 
The most common toxicities of cisplatin are ototoxicity, nephrotoxicity, and neurotoxicity. 
Cisplatin ototoxicity is caused by damage to the hair cells in the cochlea resulting first in high 
frequency hearing loss, although loss in lower frequencies are also observed in children with 
either prolonged exposure or an inherent susceptibility to cisplatin ototoxicity.
75
 High frequency 
tones are important for language development in young children, and cisplatin ototoxicity is 
more severe at younger ages of treatment. Several studies demonstrate that cisplatin ototoxicity 
is not static but worsens over time, and hearing loss may first be diagnosed as late as two years 
after therapy completion. Moreover, even children without overt ototoxicity have an advanced 
ear age and may be prone to early onset age-related hearing loss.   
 
Men with testicular cancer treated with cisplatin have a 15% decrease in glomerular function that 
is immediate and irreversible.
76
 Although this decrease is initially subclinical, similar decrements 
in renal function have been associated with increased cardiovascular and all-cause mortality. 
Neurotoxicity such as paraesthesia are also caused by exposure to cisplatin, although these are 
more commonly seen in adults than in children.    
 
Cisplatin is a heavy metal and circulating levels of cisplatin adducts can be detected in the serum 
of patients more than ten years after treatment.
77
 The degree of circulating platinum has been 
shown to correlate with the severity of neurotoxicity in adults.  
 
Up to half of patients develop evidence of pulmonary toxicity upon exposure to bleomycin. 
Although this is reversible in most patients, recent studies in testicular cancer survivors have 
found an 8% prevalence of restrictive lung disease,
78
 and a 2.5-fold elevated risk of death from 
pulmonary disease compared to the general population.
79
 
 
A two-fold increased risk of cardiovascular disease
80
 and second malignancy
81
 exists in men 
treated for testicular cancer. Of note, the increased second cancer risk occurs at a rate of 
approximately 1% per year, with no plateau.. By 75y, a seminoma patient would have a 
cumulative risk of 28% if treated at 50y, 36% if treated at 35y, and 47% if treated at 20y. 
Although the relative risk for younger age at diagnosis is not known, this trend is concerning if 
extrapolated to paediatric patients, who may be treated with the same regimen as early as 
infancy.       
  
 
CONCLUSIONS 
 
We allude to the challenges in the management of paediatric GCTs and highlight ways in which 
these have been, or can be, overcome.  Although significant challenges remain, the way forward 
has been charted. A new era of collaboration is underway, building bridges between paediatric 
and adult cooperative groups as well as across international borders. These collaborative efforts 
will allow for the development of a standardised vocabulary for staging, risk-stratification, and 
treatment approaches and for new clinical and biological insights. Options for reduction of 
therapy for those with excellent probability of cure and intensification or novel approaches for 
those with poor-risk disease will be explored. Together, these advances will allow us to approach 
the goal of curing all patients with MGCTs, and to do so with the least possible late-effects.  
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